Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume:559.99
2.75
0.01  (0.36%)
Announcement & Circular
02-01
2024
UPDATED PROGRESS IN RELATION TO THE MARKETING REVIEW OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) IN THE UNITED STATES
02-01
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
01-12
2024
INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER
01-03
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
12-06
2023
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
12-06
2023
CHANGE OF NON-EXECUTIVE DIRECTOR
12-04
2023
INNOVATIVE DRUG LURBINECTEDIN APPROVED FOR THE TREATMENT OF RELAPSED SMALL CELL LUNG CANCER IN MACAO, CHINA
12-01
2023
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
11-03
2023
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
10-31
2023
RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN CHINA
1
2
3
4
5